Active pharmaceutical ingredient Market to register $213.84

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
132
Active pharmaceutical ingredient Market to register $213.84 Bn by 2021

Sarasota, FL, Jan. 02, 2017 (GLOBE NEWSWIRE) -- According to a new report published by Zion Market Research titled “Active Pharmaceutical Ingredients Market by API Synthesis (Biotech API, Synthetic Chemical API, and HPAPI), by Type of Manufacturing (Contract Manufacturing and In-House API Manufacturing), by Type of API (Synthetic API and Biological API), by Drug Type (Branded Drugs, Generic Drugs and OTC Drugs), for Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal and Other Application - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” , global active pharmaceutical ingredient market was valued at USD 148.22 billion in 2015, is expected to reach USD 213.84 billion in 2021 and is anticipated to grow at a CAGR of 6.3% between 2016 and 2021.

APIs are frequently referred as "bulk pharmaceuticals”. The active pharmaceutical ingredient is a biologically active portion of any pharmaceutical drug. Occasionally, API needs cofactor in order to attain specific effects on the body. Some active pharmaceutical ingredients are unidentified and therefore need additional substances, which can work in combination with the API to generate the required medicinal effect on the body. In herbal medicines, the API is generally a mixture of various substances, which act collectively on the body.

Request free Sample copy of Active pharmaceutical ingredient Market @ https://www.zionmarketresearch.com/sample/act...nts-market

The market for API is expected to have the highest growth rate in the forecast period. The increasing prevalence of diabetes, neurological disorders, and other chronic diseases are the major driving factor of the global API market. One of the key drivers of the API market is an increase in the outsourcing of active pharmaceutical ingredients manufactured by pharmaceutical companies which are done to reduce both manufacturing and infrastructure costs. Such outsourced manufacturing activities are carried out by low-cost vendors in the Asia Pacific region.

However, strict regulations are one of the major challenges faced by the global API market. Such regulations are predominantly well defined in developed regions such as North America and Europe. Vendors in this market space are supposed to obey the detailed procedures prior to product commercialization.

Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/ac...nts-market

The global API market is segmented based on API synthesis, type of manufacturing, and type of API, application and by region. Depending on synthesis market is classified into biotech API, synthetic chemical API, and HPAPI. On the basis of the type of drug, the market is segmented into branded drugs, generic drugs, and OTC (Over the Counter) drugs. The branded drug segment accounted for the largest share in 2015. Different therapeutic application of the API market includes cardiology, oncology, anti-inflammatory, gastrointestinal and others. The oncology segment is anticipated to grow at the highest growth rate in coming years due to increasing prevalence of cancer worldwide.

North America is leading market for API and acquired the largest share in 2015. Asia-Pacific region is expected to emerge as fastest growing region due to low operation costs and high investments in medical research. Furthermore, the high cost of trained labor and energy are the most important factors that enforced European market to move their base to develop countries such as India and China.

Request a customized copy of report @ https://www.zionmarketresearch.com/custom/56

Sun Pharmaceuticals Industries Limited, Novartis International AG, BASF SE, Pfizer, Inc., Aurobindo, Albemarle Corporation, and Boehringer Ingelheim among others are some of the leading players in API market.  

Browse the full " Active Pharmaceutical Ingredients Market by API Synthesis (Biotech API, Synthetic Chemical API, and HPAPI), by Type of Manufacturing (Contract Manufacturing and In-House API Manufacturing), by Type of API (Synthetic API and Biological API), by Drug type (Into Branded Drugs, Generic Drugs and OTC Drugs), for Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal and Other Application - Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021 " report at  https://www.zionmarketresearch.com/report/act...nts-market

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research

Follow Us Twitter: https://twitter.com/zion_research

Contact Us: Joel John 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

iCapital Enhances Portfolio Solutions For Global Investors

Updated Category News Views 267

iCapital Enhances Portfolio Construction Tools for Investors iCapital, a leading global fintech platform, has introduced significant enhancements to its innovative portfolio construction tool, iCapital Architect. This advanced platform is designed to simplify the integration of alternative investments into traditional portfolio strategies. Financial advisors gain access...

Continue Reading
Market Adaptability: S&P 500 Faces Correction Ahead

Updated Category News Views 210

Understanding Recent Market Movements The market experienced a turbulent session recently, sending investors into a state of caution. This volatility was significantly influenced by renewed discussions around tariffs impacting trade relationships, particularly involving technology and manufacturing sectors. The Impact of Tariffs on the Market Former President Trump's...

Continue Reading
Performance Systems Integration Merges with Summit Fire & Security

Updated Category News Views 177

Performance Systems Integration Merger with Summit Fire & Security Performance Systems Integration (PSI), recognized as the leading fire and life safety solutions provider in the Pacific Northwest, has completed a merger with Summit Fire & Security LLC, which is a subsidiary of SFP Holding, Inc. This merger marks a significant collaboration that aims to enhance the safety...

Continue Reading
Candel Therapeutics Shares Optimistic Findings on CAN-3110

Updated Category News Views 159

Revealing Interim Results from Candel Therapeutics NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This...

Continue Reading
Supernus Pharmaceuticals Reaches New Heights with Strong Growth

Updated Category News Views 83

Supernus Pharmaceuticals Hits Record Stock Levels Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has achieved a remarkable milestone, as its stock recently surged to a 52-week high of $35.45. This significant increase showcases the company’s strong financial performance and growth prospects, creating a wave of optimism among investors. The stock has risen an impressive...

Continue Reading